Managing Director & Group Chief Executive Officer
BEng (Hons) DPhil (Oxon) MBA (TRIUM) JD (Melb) FIEAust

Skills and experience

Dr Behrenbruch has over two decades of radiopharmaceuticals experience and a strong track record in global healthcare and biotechnology entrepreneurship and technology commercialisation. He brings a unique blend of technical expertise an executive leadership to guide Telix as it enters the next stage of its strategy.

Dr Behrenbruch has a strong focus on purpose and values-leadership and is well versed in all aspects of running a publicly listed company as both CEO and Director in the United States and Australia.

Dr Behrenbruch holds a DPhil (PhD) in biomedical engineering from the University of Oxford, an executive MBA jointly awarded from New York University, HEC Paris and the London School of Economics (TRIUM Program) and a Juris Doctor from the University of Melbourne. He is a Fellow of Engineers Australia in the management and biomedical colleges and a Graduate of the Australian Institute of Company Directors.

Career summary

Previously, Dr Behrenbruch served as Chief Executive Officer at Mirada Solutions (now Mirada Medical Limited) (from July 2001 to December 2002), President at CTI Molecular Imaging (now Siemens Healthcare) (from August 2003 to September 2006), Chief Executive Officer at Fibron Technologies, Inc. (from June 2008 to December 2011) and Chief Executive Officer at ImaginAb, Inc (from October 2007 to February 2015). He served as a Director at Siemens Molecular Imaging Ltd (from May 2005 to September 2006), Momentum Biosciences LLC (from July 2007 to June 2009), Radius Health Ltd (now Adaptix Ltd) (from May 2009 to February 2011), Factor Therapeutics Limited (ASX: FTT) (from October 2015 to May 2021) and Amplia Therapeutics Limited (ASX: ATX) (from May 2016 to February 2020). Dr Behrenbruch was the Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre) (from October 2012 to July 2014).